Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
2 recherche sur le mot-clé 'response'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Age-Related Differences in Response to Music-Evoked Emotion Among Children and Adolescents with Autism Spectrum Disorders / K. G. STEPHENSON in Journal of Autism and Developmental Disorders, 46-4 (April 2016)
[article]
Titre : Age-Related Differences in Response to Music-Evoked Emotion Among Children and Adolescents with Autism Spectrum Disorders Type de document : Texte imprimé et/ou numérique Auteurs : K. G. STEPHENSON, Auteur ; E. M. QUINTIN, Auteur ; M. SOUTH, Auteur Année de publication : 2016 Article en page(s) : p.1142-1151 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Music Anxiety Emotion Development Skin conductance response Index. décimale : PER Périodiques Résumé : While research regarding emotion recognition in ASD has focused primarily on social cues, musical stimuli also elicit strong emotional responses. This study extends and expands the few previous studies of response to music in ASD, measuring both psychophysiological and behavioral responses in younger children (ages 8–11) as well as older adolescents (ages 16–18). Compared to controls, the ASD group demonstrated reduced skin conductance response to music-evoked emotion. Younger groups, regardless of diagnosis, showed greater physiological reactivity to scary stimuli than to other emotions. There was a significant interaction of age group and diagnostic group in identifying scary music stimuli, possibly evidencing disrupted developmental trajectories in ASD for integrating physiological and cognitive cues that may underlie symptoms of anxiety. En ligne : http://dx.doi.org/10.1007/s10803-015-2624-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=284
in Journal of Autism and Developmental Disorders > 46-4 (April 2016) . - p.1142-1151[article] Age-Related Differences in Response to Music-Evoked Emotion Among Children and Adolescents with Autism Spectrum Disorders [Texte imprimé et/ou numérique] / K. G. STEPHENSON, Auteur ; E. M. QUINTIN, Auteur ; M. SOUTH, Auteur . - 2016 . - p.1142-1151.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 46-4 (April 2016) . - p.1142-1151
Mots-clés : Autism spectrum disorder Music Anxiety Emotion Development Skin conductance response Index. décimale : PER Périodiques Résumé : While research regarding emotion recognition in ASD has focused primarily on social cues, musical stimuli also elicit strong emotional responses. This study extends and expands the few previous studies of response to music in ASD, measuring both psychophysiological and behavioral responses in younger children (ages 8–11) as well as older adolescents (ages 16–18). Compared to controls, the ASD group demonstrated reduced skin conductance response to music-evoked emotion. Younger groups, regardless of diagnosis, showed greater physiological reactivity to scary stimuli than to other emotions. There was a significant interaction of age group and diagnostic group in identifying scary music stimuli, possibly evidencing disrupted developmental trajectories in ASD for integrating physiological and cognitive cues that may underlie symptoms of anxiety. En ligne : http://dx.doi.org/10.1007/s10803-015-2624-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=284 Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis / Spyridon SIAFIS in Molecular Autism, 13 (2022)
[article]
Titre : Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis Type de document : Texte imprimé et/ou numérique Auteurs : Spyridon SIAFIS, Auteur ; O?ulcan ÇIRAY, Auteur ; Hui WU, Auteur ; Johannes SCHNEIDER-THOMA, Auteur ; Irene BIGHELLI, Auteur ; Marc KRAUSE, Auteur ; Alessandro RODOLICO, Auteur ; Anna CERASO, Auteur ; Giacomo DESTE, Auteur ; Maximilian HUHN, Auteur ; David FRAGUAS, Auteur ; Antonia SAN JOSE CACERES, Auteur ; Dimitris MAVRIDIS, Auteur ; Tony CHARMAN, Auteur ; Declan G. MURPHY, Auteur ; Mara PARELLADA, Auteur ; Celso ARANGO, Auteur ; Stefan LEUCHT, Auteur Article en page(s) : 10 p. Langues : Anglais (eng) Mots-clés : Adolescent Adult Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder/drug therapy Child Humans Network Meta-Analysis Oxytocin/therapeutic use Risperidone/therapeutic use Adhd Anxiety Autism Caregiver stress Irritability Meta-analysis Response Restricted and repetitive behaviors Social communication Treatment Index. décimale : PER Périodiques Résumé : BACKGROUND: There is still no approved medication for the core symptoms of autism spectrum disorder (ASD). This network meta-analysis investigated pharmacological and dietary-supplement treatments for ASD. METHODS: We searched for randomized-controlled-trials (RCTs) with a minimum duration of seven days in ClinicalTrials.gov, EMBASE, MEDLINE, PsycINFO, WHO-ICTRP (from inception up to July 8, 2018), CENTRAL and PubMed (up to November 3, 2021). The co-primary outcomes were core symptoms (social-communication difficulties-SCD, repetitive behaviors-RB, overall core symptoms-OCS) measured by validated scales and standardized-mean-differences (SMDs). Associated symptoms, e.g., irritability/aggression and attention-deficit/hyperactivity disorder (ADHD) symptoms, dropouts and important side-effects, were investigated as secondary outcomes. Studies in children/adolescents and adults were analyzed separately in random-effects pairwise and network meta-analyses. RESULTS: We analyzed data for 41 drugs and 17 dietary-supplements, from 125 RCTs (n=7450 participants) in children/adolescents and 18 RCTs (n=1104) in adults. The following medications could improve at least one core symptom domain in comparison with placebo: aripiprazole (k=6 studies in analysis, SCD: SMD=0.27 95% CI [0.09, 0.44], RB: 0.48 [0.26, 0.70]), atomoxetine (k=3, RB:0.49 [0.18, 0.80]), bumetanide (k=4, RB: 0.35 [0.09, 0.62], OCS: 0.61 [0.31, 0.91]), and risperidone (k=4, SCM: 0.31 [0.06, 0.55], RB: 0.60 [0.29, 0.90]; k=3, OCS: 1.18 [0.75, 1.61]) in children/adolescents; fluoxetine (k=1, RB: 1.20 [0.45, 1.96]), fluvoxamine (k=1, RB: 1.04 [0.27, 1.81]), oxytocin (k=6, RB:0.41 [0.16, 0.66]) and risperidone (k=1, RB: 0.97 [0.21,1.74]) in adults. There were some indications of improvement by carnosine, haloperidol, folinic acid, guanfacine, omega-3-fatty-acids, probiotics, sulforaphane, tideglusib and valproate, yet imprecise and not robust. Confidence in these estimates was very low or low, except moderate for oxytocin. Medications differed substantially in improving associated symptoms, and in their side-effect profiles. LIMITATIONS: Most of the studies were inadequately powered (sample sizes of 20-80 participants), with short duration (8-13 weeks), and about a third focused on associated symptoms. Networks were mainly star-shaped, and there were indications of reporting bias. There was no optimal rating scale measuring change in core symptoms. CONCLUSIONS: Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317. En ligne : http://dx.doi.org/10.1186/s13229-022-00488-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477
in Molecular Autism > 13 (2022) . - 10 p.[article] Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis [Texte imprimé et/ou numérique] / Spyridon SIAFIS, Auteur ; O?ulcan ÇIRAY, Auteur ; Hui WU, Auteur ; Johannes SCHNEIDER-THOMA, Auteur ; Irene BIGHELLI, Auteur ; Marc KRAUSE, Auteur ; Alessandro RODOLICO, Auteur ; Anna CERASO, Auteur ; Giacomo DESTE, Auteur ; Maximilian HUHN, Auteur ; David FRAGUAS, Auteur ; Antonia SAN JOSE CACERES, Auteur ; Dimitris MAVRIDIS, Auteur ; Tony CHARMAN, Auteur ; Declan G. MURPHY, Auteur ; Mara PARELLADA, Auteur ; Celso ARANGO, Auteur ; Stefan LEUCHT, Auteur . - 10 p.
Langues : Anglais (eng)
in Molecular Autism > 13 (2022) . - 10 p.
Mots-clés : Adolescent Adult Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder/drug therapy Child Humans Network Meta-Analysis Oxytocin/therapeutic use Risperidone/therapeutic use Adhd Anxiety Autism Caregiver stress Irritability Meta-analysis Response Restricted and repetitive behaviors Social communication Treatment Index. décimale : PER Périodiques Résumé : BACKGROUND: There is still no approved medication for the core symptoms of autism spectrum disorder (ASD). This network meta-analysis investigated pharmacological and dietary-supplement treatments for ASD. METHODS: We searched for randomized-controlled-trials (RCTs) with a minimum duration of seven days in ClinicalTrials.gov, EMBASE, MEDLINE, PsycINFO, WHO-ICTRP (from inception up to July 8, 2018), CENTRAL and PubMed (up to November 3, 2021). The co-primary outcomes were core symptoms (social-communication difficulties-SCD, repetitive behaviors-RB, overall core symptoms-OCS) measured by validated scales and standardized-mean-differences (SMDs). Associated symptoms, e.g., irritability/aggression and attention-deficit/hyperactivity disorder (ADHD) symptoms, dropouts and important side-effects, were investigated as secondary outcomes. Studies in children/adolescents and adults were analyzed separately in random-effects pairwise and network meta-analyses. RESULTS: We analyzed data for 41 drugs and 17 dietary-supplements, from 125 RCTs (n=7450 participants) in children/adolescents and 18 RCTs (n=1104) in adults. The following medications could improve at least one core symptom domain in comparison with placebo: aripiprazole (k=6 studies in analysis, SCD: SMD=0.27 95% CI [0.09, 0.44], RB: 0.48 [0.26, 0.70]), atomoxetine (k=3, RB:0.49 [0.18, 0.80]), bumetanide (k=4, RB: 0.35 [0.09, 0.62], OCS: 0.61 [0.31, 0.91]), and risperidone (k=4, SCM: 0.31 [0.06, 0.55], RB: 0.60 [0.29, 0.90]; k=3, OCS: 1.18 [0.75, 1.61]) in children/adolescents; fluoxetine (k=1, RB: 1.20 [0.45, 1.96]), fluvoxamine (k=1, RB: 1.04 [0.27, 1.81]), oxytocin (k=6, RB:0.41 [0.16, 0.66]) and risperidone (k=1, RB: 0.97 [0.21,1.74]) in adults. There were some indications of improvement by carnosine, haloperidol, folinic acid, guanfacine, omega-3-fatty-acids, probiotics, sulforaphane, tideglusib and valproate, yet imprecise and not robust. Confidence in these estimates was very low or low, except moderate for oxytocin. Medications differed substantially in improving associated symptoms, and in their side-effect profiles. LIMITATIONS: Most of the studies were inadequately powered (sample sizes of 20-80 participants), with short duration (8-13 weeks), and about a third focused on associated symptoms. Networks were mainly star-shaped, and there were indications of reporting bias. There was no optimal rating scale measuring change in core symptoms. CONCLUSIONS: Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317. En ligne : http://dx.doi.org/10.1186/s13229-022-00488-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477